Kurtoglu Metin's Form 4 filing
Cartesian Therapeutics, Inc. (RNAC) · filed Nov 18, 2024
- Accession no.
- 0001453687-24-000132
- Filed
- Nov 18, 2024
- Trade date
- Nov 14-18, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.44M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kurtoglu MetinCIK 0002000284 | Officer (Chief Technology Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 | Common Stock | MOption exerciseAcquired | +25,900 | $1.41 | +$36,519 | 76,933 | Direct | |
| Nov 14, 2024 | Common Stock | SSaleDisposed | −21,900 | $16.33F1 | −$357,627 | 55,033 | Direct | |
| Nov 14, 2024 | Common Stock | SSaleDisposed | −4,000 | $17.06F2 | −$68,240 | 51,033 | Direct | |
| Nov 15, 2024 | Common Stock | MOption exerciseAcquired | +22,068 | $1.41 | +$31,115.88 | 73,101 | Direct | |
| Nov 15, 2024 | Common Stock | SSaleDisposed | −22,068 | $17.20F3 | −$379,569.6 | 51,033 | Direct | |
| Nov 18, 2024 | Common Stock | MOption exerciseAcquired | +34,400 | $1.41 | +$48,504 | 85,433 | Direct | |
| Nov 18, 2024 | Common Stock | SSaleDisposed | −16,672 | $18.19F4 | −$303,263.68 | 68,761 | Direct | |
| Nov 18, 2024 | Common Stock | SSaleDisposed | −17,728 | $18.58F5 | −$329,386.24 | 51,033 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 | Common Stock | MOption exerciseDisposed | −25,900 | –F7 | – | 187,920 | Direct | |
| Nov 15, 2024 | Common Stock | MOption exerciseDisposed | −22,068 | –F7 | – | 165,852 | Direct | |
| Nov 18, 2024 | Common Stock | MOption exerciseDisposed | −34,400 | –F7 | – | 131,452 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.12. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.50 to $18.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.50 to $18.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F7
On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.
Referenced by the price of 3 transactions in Table II.